The patent application WO2020261041, related to abrocitinib, was published by Google Patents. This application describes a process for preparing abrocitinib [1].
What does the WO2020261041 patent application cover?
WO2020261041 details a specific synthetic route for manufacturing abrocitinib, an active pharmaceutical ingredient [1]. The disclosed process aims to provide an efficient and scalable method for producing the drug [1]. Abrocitinib is a Janus kinase 1 (JAK1) inhibitor used for the treatment of atopic dermatitis [2].
What is abrocitinib?
Abrocitinib is a medication that works by selectively inhibiting the JAK1 enzyme [2]. This inhibition helps to reduce inflammation associated with certain immune-mediated diseases, such as atopic dermatitis [2]. It is taken orally [2].
When does abrocitinib's patent protection expire?
Patent protection timelines for pharmaceuticals are complex and can involve multiple patents covering the drug substance, its manufacturing processes, and its uses. Information on specific patent expiry dates for abrocitinib, including the patent family associated with WO2020261041, can be found on resources like DrugPatentWatch.com [3]. These timelines are crucial for understanding when generic versions might become available.
Who developed abrocitinib?
Abrocitinib was developed by Pfizer Inc. [2].
How does abrocitinib compare to other atopic dermatitis treatments?
Abrocitinib is part of a class of treatments for atopic dermatitis that includes topical therapies, oral corticosteroids, and other targeted therapies like other JAK inhibitors and biologics [4]. Its efficacy and safety profile are compared against these existing treatment options during clinical development and post-market surveillance.
What are the potential risks or side effects of abrocitinib?
Like all medications, abrocitinib has potential side effects. Common side effects may include acne, upper respiratory tract infections, and nausea [2]. More serious risks, such as infections, blood clots, and malignancy, have been associated with JAK inhibitors [2].
How can I find more information on abrocitinib patents?
Resources like DrugPatentWatch.com offer databases and analysis of pharmaceutical patents, including those for abrocitinib [3]. These platforms can provide detailed information on patent families, expiry dates, and legal challenges, which are essential for understanding market exclusivity and the potential for generic competition.
What is the role of process patents?
Process patents, like the one described in WO2020261041, protect the specific methods used to manufacture a drug [1]. While a patent on the drug substance itself grants broad protection, process patents can offer additional layers of exclusivity by preventing competitors from using the same efficient manufacturing techniques, even if the drug compound is no longer under patent protection [1].
Sources
1. Google Patents. WO2020261041.
2. U.S. Food & Drug Administration. Cibinqo (abrocitinib) Prescribing Information.
3. DrugPatentWatch.com.
4. National Eczema Association. Treatments for Atopic Dermatitis.